Skip to main content

Dronabinol Safe, Effective for Alzheimer Disease With Agitation

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 9, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Oct. 9, 2024 -- Dronabinol is safe and effective for the treatment of Alzheimer disease with agitation (Agit-AD), according to a study presented at the annual meeting of the International Psychogeriatric Association, held from Sept. 25 to 27 in Buenos Aires, Argentina.

Paul Rosenberg, M.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a three-week, placebo-controlled, double-blind, randomized clinical trial of dronabinol (target dose, 10 mg daily) in 80 inpatients with severe Agit-AD.

The researchers found that for both Pittsburgh Agitation Scale (PAS) and Neuropsychiatric Inventory, Clinician Version (NPI-C) Agitation and Aggression (A/A) subscales, the difference in rate of change was statistically significant, with participants assigned to the dronabinol arm declining and improving more over the trial. The between-arm difference in change over three weeks divided by the baseline standard deviation (the effect size) was 0.53 and 0.35 for PAS and NPI-C A/A, respectively. There were no significant differences between the groups for the secondary outcomes of NPI-C Sleep, NPI-C Total, Cohen-Mansfield Agitation Inventory, Caregiver Distress, and Alzheimer Disease Cooperative Study-Activities of Daily Living, nor for NPI-C Disinhibition, NPI-C Irritability, and the Modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. Additionally, there were no significant differences in either adverse events (AEs) or serious AEs between the groups (37 in the placebo arm and 43 in the dronabinol arm).

"This pilot trial could open the door to 'repurposing' dronabinol as a novel and safe treatment for Agit-AD with significant public health impact," the authors write.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Herpes Simplex Virus Type 1 May Affect Risk for Alzheimer Disease

THURSDAY, May 22, 2025 -- Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States...

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

TUESDAY, May 20, 2025 -- Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a...

Overwork Tied to Structural Changes in Brains of Health Care Workers

MONDAY, May 19, 2025 -- Overwork in health care workers is associated with structural brain changes, particularly in regions linked to cognition and emotion, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.